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peart failure (HF) has been the subject of a number of
mportant published clinical and translational investigations
ver the past year. We also anticipate that updates of the
merican professional societies’ major clinical guidelines
ill be published later this year. In this article, we summa-
ize the year’s publications that we believe have the greatest
linical relevance to the understanding and management of
he HF syndrome.
athophysiology and Diagnostic Testing
enetics of cardiomyopathies. With the increasing avail-
bility of commercially available testing for common genetic
utations found in patients with inherited cardiomyopathy,
here is now a serious dialogue as to how these tests should
est be used (1). It is becoming increasingly clear that the 8
ommonly tested genes for hypertrophic cardiomyopathy
re especially prevalent in childhood cases (2). Probands
ith these gene mutations (found in about 60% of cases)
ppear to have poorer long-term prognosis as a group
ompared with those having no identifiable mutations (3).
nterestingly, the use of genetic counseling and testing of
elatives has remained relatively uncommon despite the
vailability of preventive measures, in part because the
isk-benefit of genetic testing is still uncertain and because
ncomplete penetrance is common (4). A similar molecular
enetic diagnostic approach in patients with dilated cardio-
yopathy has been less productive, with only about 10% of
ases identified by a 6-gene mutation panel (5) and another
% of cases identified by lamin A/C mutation analysis (6).
here is hope that genetic findings may ultimately provide
dditional insight for patients and their family members
ith these otherwise unexplained cardiomyopathies.
A “genetic beta-blockade” phenomenon has been re-
orted in patients of African-American descent (7). In
everal patient cohorts, a polymorphism in GRK5
glutamine¡leucine) was found in approximately 10-fold
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han in Caucasians. The presence of GRK5-Leu41 was asso-
iated with diminished isoproterenol-stimulated -adrenergic
eceptor signaling effects on the basis of desensitization of
igand-occupied receptors (7). This genetic profile may be
rotective against disease progression (rather than disease
nset) in a manner similar to treatment with beta-blockers.
he investigators provided proof of concept by demonstrat-
ng remarkably lower event rates for patients with GRK5-
eu41 polymorphism in 2 separate cohorts, although the
ctual number of events was small. Nevertheless, one of the
reatest challenges of pharmacogenetic analyses related to
ene polymorphisms of neurohormonal pathways is the
ssociative nature of the analysis. Such analyses are some-
imes plagued by biases and lack of reproducibility (8). An
xample of this confounding influence can be seen in a study
9) that attempted to compare the effects of 2 distinct
eta-adrenergic blocking agents on the basis of 5 different
olymorphisms in the adrenergic signaling pathway. The
nvestigators found no impact of these polymorphisms on
he variable responses to different beta-blockers, in contrast
ith the remarkable differences previously seen with bucin-
olol in those with the Arg389Arg ADBR1 allele (10).
learly, the impact of genetic profiling on treatment re-
ponses needs further validation and careful scrutiny. Nev-
rtheless, the field is moving forward, and both investigator
nd commercial interests are growing stronger.
The incomplete penetrance of monogenetic mutations
as allowed for emergence of an alternative strategy using a
ranscriptomic approach, although the need for both tissue
amples and an overwhelming amount of data remain
mportant obstacles. Recent demonstration (11) of the
bility of a targeted transcriptomic array from endomyocar-
ial biopsy samples in patients with new-onset HF to
istinguish between favorable and unfavorable prognosis is
romising. Clearly, current recommendations (12) do not
avor routine endomyocardial biopsy as part of standard
linical evaluation, but this may change with improvement
n diagnostic techniques, and endomyocardial biopsy is
ndicated for specific diagnostic purposes.
iomarkers in HF. The field of HF biomarkers continues
o grow exponentially, although the gap between published
vidence and clinical practice remains (13). Published re-
orts are becoming bloated with descriptive studies that
atch a specific biomarker with a specific diagnostic feature
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Year in HF November 11, 2008:1671–8r match a cutoff value to predict a specific risk profile. For
xample, more data regarding the potential prognostic role
f ST2 were reported this year. Baseline (14) as well as
ollow-up (15) measurements of ST2 levels in patients
dmitted to the hospital with HF or with ST-elevation
yocardial infarction (16) have been reported. Other novel
arkers with incremental prognostic value recently described
nclude osteopontin (17), copeptin (18), advanced glycation
nd products (19), and methylated arginine metabolites (20),
o name a few (all yet to be clinically available).
Using biomarkers as surrogates of therapeutic responses
as been the subject of several clinical studies this year.
nterestingly, the lack of improvement in neurohormonal
evels in the BEST (Beta-blocker Evaluation of Survival
tudy) is consistent with the lack of efficacy of bucindolol
21). In the ALOFT (Aliskiren Observation of Heart
ailure Treatment) study, where aliskiren (150 mg daily)
as compared to placebo as an add-on therapy for 12 weeks
n 302 patients with HF (New York Heart Association
NYHA] functional class II to VI, B-type natriuretic
eptide [BNP] 100 pg/ml, creatinine 2 mg/dl), signif-
cant reductions in neurohormonal activity were observed
ithout increasing adverse drug effects (22). Still, not all
avorable changes in biomarker levels are associated with
avorable long-term outcomes, as in the case of CORONA
Controlled Rosuvastatin Multinational Trial in Heart Fail-
re), where a substantial reduction in high-sensitivity
-reactive protein did not match the primarily neutral
esults of the study (23). However, very few therapeutic
tudies have provided insight into how these biomarkers can
elp in the clinical management of patients with HF. The
PT-CHF (Oxypurinol Therapy for Congestive Heart
ailure) study published this year (24) outlined the potential
enefits of xanthine oxidase inhibition by oxypurinol in
atients with HF who demonstrate elevated uric acid levels.
The logistics of applying biomarkers to clinical practice
re elegantly illustrated in a study conducted in a large
ritish general practice population of older patients with
iabetes mellitus or ischemic heart disease (i.e., Stage A).
ollowing initial BNP testing, approximately 19% of these
inimally symptomatic patients were found to have ele-
ated plasma BNP levels, and subsequently 10% had per-
istently elevated plasma BNP levels on repeated testing.
nitiation or up-titration of evidence-based HF treatment
acilitated normalized BNP levels in 28% of patients (25).
iabetic retinopathy has been identified as another risk
actor for HF (26). Indeed, early identification of at-risk
atients and aggressive risk factor modification and thera-
eutic interdiction are the core promise of prevention, as
utlined in a recent consensus statement (27). Because
imple clinical characteristics can identify individuals at risk
f developing HF (28), we believe that biomarker-guided
trategies should be pursued not simply for the sake of
etecting the presence of structural heart diseases, but also
o signal appropriate interventions in at-risk individuals. areventing disease, rather than predicting events, should
emain the primary focus.
ardiorenal interactions. The concept of renal preserva-
ion in patients with acute heart failure syndrome (AHFS)
as become more widely recognized, but determining the
recise mechanism whereby an individual patient’s cardio-
enal function becomes impaired in this syndrome is chal-
enging. Traditionally, inadequate renal perfusion has been
he prevailing hypothesis and has been attributed to a
educed cardiac output and low renal blood flow. A rise in
erum creatinine still provides a crude estimate of renal
ompromise and worsening prognosis (29,30). Persistent
yponatremia is also a clear marker for poor survival
29,31,32). There is now interest in examining the utility of
lood urea nitrogen, both as a single time point and by
ncrease over time, as a strong prognostic marker in both
table patients (33) and in those with decompensated HF
34). Newer markers have yet to be widely examined in this
opulation. Cystatin C can identify a subset of patients with
ormal serum creatinine levels and a poor outcome (35).
nderlying conditions (e.g., diastolic dysfunction, right
F) that contribute to worsening venous congestion can
lso be associated with higher cystatin C levels (36,37) and
greater likelihood of worsening renal function (30). In the
etting of chronic HF, shorter leukocyte telomere length has
een associated with renal insufficiency (38), but the mech-
nisms have remained unexplained.
The traditional simple model of cardiorenal syndrome
ssumes that impaired cardiac output contributes to dimin-
shed renal perfusion, leading to reduced filtration and/or
enal ischemia. Clearly, the degree of antecedent intrinsic
enal disease is very important, and hemodynamic alter-
tions contribute only in part to the development of acute
orsening renal function (39). Several groups (30,40) have
ecently rediscovered the importance of venous congestion
s a contributing factor to the progression of worsening
enal function independent of forward cardiac output. How-
ver, routine hemodynamically guided therapy does not
ppear to provide any substantial advantage in managing these
atients (39). An extrarenal component of abdominal conges-
ion leading to raised intra-abdominal pressure may worsen on
entral venous pressures (41) and may contribute to renal
unction impairment (42). Persistently raised intra-abdominal
ressures despite aggressive medical therapy may warrant
urther investigation and treatment (43). The challenge is to
nd safe and effective ways to relieve salt and water retention.
efining diastolic HF. The struggle to best define the
iastolic HF (or HF with preserved ejection fraction
HFpEF]) population is persistent. Observations from the
EP-CHF (Perindopril in Elderly People with Chronic
eart Failure) and the I-PRESERVE (Irbesartan in Heart
ailure with Preserved Systolic Function) trials indicate that
xisting inclusion criteria for diastolic HF are heteroge-
eous, and long-term clinical outcomes are highly depen-
ent on markers of severity such as natriuretic peptide levels
nd previous hospitalizations for HF exacerbations (44,45).
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November 11, 2008:1671–8 Year in HFhe updated consensus statement published by the Euro-
ean Society of Cardiology this year (46) has proposed 3
bligatory conditions for the diagnosis of HFpEF: the
resence of signs and symptoms of congestive HF, the
resence of a normal or mildly abnormal left ventricular
LV) systolic function (left ventricular ejection fraction
LVEF] 40%), and evidence of diastolic LV dysfunction
including abnormal LV relaxation, filling, diastolic distensi-
ility, and diastolic stiffness). Besides standard invasive and
chocardiographic measurements, there is a heavy emphasis on
he role of tissue Doppler indexes. However, there is contro-
ersy as to whether diastolic abnormalities are always present in
uch patients. Notably, LV hypertrophy and clear laboratory
vidence of diastolic impairment appear to be absent in some
atients with clinical HF and HFpEF even in the setting of
ypertrophic cardiomyopathy (47), suggesting that we still do
ot understand this syndrome very well.
harmacologic Treatment
tandard pharmacologic therapy. Contemporary outpa-
ient management of HF has been examined in the
MPROVE-HF (Registry to Improve the Use of Evidence-
ased Heart Failure Therapies in the Outpatient Setting).
lthough use of standard neurohormonal blocking agents was
igh in the 80% to 86% range, aldosterone receptor antagonists
ere prescribed in only 36% of eligible patients, and rates of
evice therapies were also lower, both decreasing with increase
n age (48). Both registry and post-hoc trial data analysis
lso suggest (49,50) that unless withdrawal is deemed
learly necessary, beta-adrenergic blockers should be
aintained during an episode of decompensated HF.
An elegant prospective study of a practical nature (51)
escribed the fallacy of logical deduction regarding diuretic
se and dosing as a “cause” of morbidity and mortality, a
erspective that has been repeatedly found in many post-hoc
nalyses. In 183 patients with advanced HF, the prognostic
alue of high-dose (80 mg/day furosemide equivalent)
iuretic therapy was negated when adjusted for clinical
tability (which is not readily available in most databases),
uggesting that diuretic dosing is simply a marker, rather
han a cause, of poor prognosis (52). This highlights the
nduring value of careful clinical investigations to clarify the
ssues raised by interrogating large databases (53).
tatins in HF. The CORONA (Controlled Rosuvastatin
ultinational Trial in Heart Failure) trial was the focus of
ebate regarding the potential role of statin therapy in
hronic HF. CORONA was a multicenter, randomized-
ontrolled, placebo-controlled trial of 5,011 older patients
age 60 years, mean age 73 years) with ischemic cardio-
yopathy (LVEF 40% for NYHA functional class III to
V or LVEF35% for NYHA functional class II). Patients
ere randomized to either rosuvastatin at 10 mg daily or
lacebo and received a median of 2.7 years follow-up (23).
he study did not reach the primary combined end point ofardiovascular death, nonfatal myocardial infarction, or tonfatal stroke (hazard ratio [HR]: 0.92; 95% confidence
nterval [CI]: 0.83 to 1.02; p  0.12) or any coronary event
nd point (HR: 0.92; 95% CI: 0.82 to 1.04; p  0.18)
Fig. 1). However in post-hoc analysis, there was a trend for
ewer cardiovascular hospitalizations and HF hospitaliza-
ion in the rosuvastatin group. These relatively tepid results
re in stark contrast with the many positive findings of statin
herapy in a broad range of patient populations and chal-
enge the large volume of research implicating broad bene-
ts of statin therapy in patients with HF (54). In the
ecently reported GISSI-HF (Gruppo Italiano per lo Studio
ella Sopravvivenza nell’Infarto Miocardico–Insufficienza
ardiaca) trial, rosuvastatin also did not demonstrate a
eduction in mortality (adjusted HR: 1.00; 95% CI: 0.90 to
.12; p 0.943) or cardiovascular hospitalizations (adjusted
R: 1.01; 95% CI: 0.91 to 1.11; p  0.903), independent of
nderlying etiology (55). Therefore, the current level of evi-
ence has yet to support routine statin use in patients with HF.
asoactive therapy. Nesiritide was the subject of a large
andomized trial in ambulatory patients with severe HF,
nd intermittent administration was found to be safe but not
ffective in achieving its end points (56). Two prospective
andomized studies in patients admitted with decompen-
ated HF and underlying renal insufficiency also demon-
trated a neutral impact of nesiritide administration on renal
unction (57,58). High-dose boluses of intravenous nitro-
lycerin given in the emergency department setting were
ssociated with fewer in-hospital cardiac or respiratory
omplications in an open-label study, even though length of
tay and readmissions were similar (59). In contrast, an
bservational study of patients with advanced low-output
F (60) found that the use of intravenous sodium nitro-
russide was beneficial in improving hemodynamic de-
angements, and it allowed for the implementation of oral
asodilator therapy at discharge. These studies highlight the
mportance (and potential benefits) of careful patient selec-
ion and titration of vasodilators when used in the AHFS
etting, which is the primary focus of an ongoing, very large
ultinational clinical trial of nesiritde.
There are exciting new compounds on the horizon that are
lso worth mentioning. First, a unique lusitropic and inotropic
gent called istaroxime was tested in HORIZON-HF (A
hase II Trial to Assess Hemodynamic Effects of Istar-
xime in Patients with Worsening Heart Failure and
educed Left Ventricular Systolic Function). Istaroxime
emonstrated significant hemodynamic and diastolic vol-
me improvement over placebo without a noticeable in-
rease in arrhythmias, ischemia, or myocardial oxygen con-
umption (61). Another compound has recently made its
ebut: a synthetic chimeric hybrid natriuretic peptide based
n the recognized properties of 2 different members of the
atriuretic peptide family. It was specifically designed to
etter enhance renal function without causing hypotension
62). Early-phase human studies are currently underway.
Regarding the role of vasodilator therapy in chronic HF,
here is accruing interest in the use of sildenafil in patients
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Year in HF November 11, 2008:1671–8ith chronic HF because of its vasoactive effects incremen-
al to standard medical therapy. In a small mechanistic
tudy, patients treated with 6 months of sildenafil demon-
trated greater improvements in brachial artery flow-
ediated dilatation, cardiopulmonary exercise testing in-
exes, and ergoreflex testing data when compared with
hose receiving placebo (63). This was also evident in
atients with secondary pulmonary hypertension treated
ith sildenafil (64).
anaging diastolic HF. Amidst the debate regarding the
efinition and therapeutic regimen to best manage diastolic
F, the Hong Kong Diastolic Heart Failure Study provided
ome interesting insight (65). This prospective, multicenter,
pen-label study (with a blinded end point) randomized 150
atients with preserved LV function (LVEF 45%) and
ecent HF admission to diuretics only, diuretics with
amipril, or diuretics with irbesartan. Despite improved
uality-of-life scoring, outcomes were not different among
he groups, except for a very slight improvement in 6-min
alk distances in the ramipril and irbesartan groups (65).
eadmission rates were similar, although both ramipril and
rbesartan demonstrated improved tissue Doppler indexes
nd lower plasma natriuretic peptide levels at follow-up
hen compared with those receiving only diuretic therapy,
espite a similar reduction in blood pressure. These results,
hough promising, were underpowered to provide reassur-
nce that improvement in echocardiographic and biochem-
cal surrogates corresponded to improved clinical outcomes.
The incremental role of aldosterone receptor antagonism
n reversing cardiac remodeling has been challenged in a
mall, prospective mechanistic study (66) in asymptomatic
atients with moderate-to-severe aortic stenosis but preserved
V systolic function. Patients randomized to eplerenone failed
o demonstrate any beneficial effect on myocardial structure,
everity of aortic valve stenosis, or LV systolic and diastolic
erformance when compared with placebo.
anaging anemia in HF. Anemia is associated with poor
ong-term outcomes in patients with HF, but much of the
emoglobin data have focused on levels derived at a single
ime point with a single cutoff value. A large, single-center
xperience observing sequential measurements over time
ndicated that almost one-half of the anemia resolved
ithout any specific therapy, and the outcomes for those
ith resolution were comparable to those without anemia
67). Two recent studies comparing intravenous iron ad-
inistration with placebo clearly demonstrated reduction in
lasma natriuretic peptide levels (68), systemic cytokines
69), and exercise capacity (70). Reports of 2 early-phase
tudies have highlighted the potential benefit of replace-
ent therapy with darbepoetin-alpha in anemic patients
ith HF (71,72), which was associated with improvement
n echocardiographic indexes when compared with placebo
73). This concept is being tested in a multicenter study.
enal preservation in AHFS. Even though there is
roader acceptance for the use of ultrafiltration for salt andFigure 1 Primary Results From the CORONA Trial
Kaplan-Meier curve for (A) primary outcome of cardiovascular death, nonfatal
myocardial infarction, or nonfatal stroke, (B) all-cause mortality, and (C) any
coronary event.uid removal, a small but carefully performed randomized
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November 11, 2008:1671–8 Year in HFtudy (74) comparing intravenous diuretic therapy with
ltrafiltration did not find significant differential impact on
enal hemodynamics. Another trial using continuous aortic
ow augmentation aimed at preserving renal function (75)
lso failed to demonstrate noticeable clinical benefits and
as associated with increased bleeding. In contrast, clinical
nvestigations regarding the role of adenosine A1 receptor
ntagonism seem to be going in the right direction. The
esults of the pilot phase of the large Phase III trial
valuating add-on intravenous rolofylline in AHFS were
ighlighted in the American College of Cardiology 2008
cientific Sessions. Among the 301 patients with AHFS
nd impaired renal function (creatinine clearance 20 to 80
l/min) and volume overload, increasing success/decreasing
reatment failures (defined as death, rehospitalization, or
orsening HF or renal function), as well as improving
erum creatinine were associated with increasing rolofylline
osing (up to 30 mg/day) (75).
onpharmacologic Treatment
ate and rhythm management in HF. This year saw the
resentation of several landmark clinical studies that provide
seful information regarding the management of atrial
brillation in patients with HF. The AF-CHF (Atrial
ibrillation in Congestive Heart Failure) trial enrolled 1,376
atients with systolic HF (LVEF35%, NYHA functional
lass II to III) and found no significant differences between
outine rate and rhythm-control strategies in reducing
ong-term clinical outcomes (including death, stroke, or
orsening HF) (76). These findings were not surprising,
onsidering the fact that the long-term predictors of adverse
linical outcomes following cardioversion for atrial fibrilla-
ion were not the rhythm, but predominantly inadequate
F treatment regimens and comorbidities (77,78).
The challenge of ventricular tachyarrhythmia (so-called
lectrical storm) is becoming increasingly common in the
ra of widespread defibrillator implantation, and the poten-
ial benefits of contemporary catheter ablation have been
emonstrated in an Italian series published this year (79).
everal groups (80–82) also have reported their experience
ith catheter ablation of premature ventricular contractions
s a potential strategy in the reversal of LV dysfunction,
ighlighting an overlooked but potentially treatable cause of
ardiomyopathy.
ardiac resynchronization therapy (CRT) in HF. The
eld of CRT continues to catalyze interdisciplinary inves-
igations, especially regarding the role of echocardiography
n the prediction and assessment of treatment responses.
he first was the RethinQ (Resynchronization Therapy in
ormal QRS) study (83), which tested the hypothesis that
orrection of an echocardiographically defined mechanical
yssynchrony independent of conduction delay may produce
linical benefits in the form of improving functional capacity
nd cardiac performance. However, the 172-patient study
howed similar outcomes with or without CRT, although lhe study was limited by the relatively short follow-up
uration and low event rates (83). The second trial was the
EVERSE (Resynchronization Reverses Remodeling in
ystolic Left Ventricular Dysfunction) study, presented at
he American College of Cardiology meeting (75), that
howed benefit of early CRT in preventing or even reversing
rogression of LV impairment as well as reducing time to
rst HF hospitalization in 610 patients with wide QRS but
ild symptoms. Critics may argue that the trial missed its
ntended primary end point of improving symptoms and
uality-of-life measures, but in the CARE-HF (Cardiac
esynchronization in Heart Failure) subanalysis, symptom
everity appeared to provide less important prognostic
nformation than other criteria (84). These results are
onsistent with subgroup analyses from prior studies that
ncluded NYHA functional class II patients and highlight
he importance of adhering to established criteria of QRS
nd echocardiographic criteria for LVEF for CRT indica-
ions (85). The current challenge is to justify the risks and
alidate the benefits, which demands further clinical inves-
igation in larger populations.
Identification of before-implantation predictors of re-
ponse to CRT has been controversial. In the CARE-HF
tudy population, greater interventricular mechanical delay,
ore severe cardiac dyssynchrony, and low systolic blood
ressure appeared to obtain greater benefits from CRT (86).
learly, “responders” to CRT often demonstrate reversal of
ardiac remodeling and morphologic as well as molecular
mprovement (87–89). The results of the PROSPECT
Predictors of Response to Cardiac Resynchronization
herapy) study (90) demonstrated that in the 69% of the
26 patients who improved following CRT, no single
chocardiographic measure of dyssynchrony was reliable in
redicting responders, which can be attributable in part to
nterobserver variability when making these measurements.
echanical support for advanced HF. Treatment for
nd-stage HF remains challenging. This year, we witnessed
he approval of the HeartMate II (Thoratec Corporation,
leasanton, California), the first nonpulsatile left ventricular
ssist device (LVAD), as a bridge to cardiac transplantation.
hese nonpulsatile LVADs provide improvement equiva-
ent to traditional pulsatile LVADs in exercise capacity and
ymptom relief, even though the traditional LVADs
chieved greater unloading (91). Ventricular restoration
urgery with the CorCap (Acorn Cardiovascular, St. Paul,
innesota) device also led to favorable long-term results in
reventing cardiac remodeling, justifying additional studies
92,93). Implantable electrophysiological device therapy has
eached beyond simple pacing or defibrillation functions.
onexcitatory, cardiac contractile modulation devices have
urther demonstrated proof-of-concept clinical effects in
hase II studies and associated mechanistic illustration of
p-regulation of myocardial contractile genes (94,95).
utcome measures. There are new data (96) to suggest
hat different factors may have varying implications for
ong-term outcomes. High blood pressure and arrhythmias,
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Year in HF November 11, 2008:1671–8or example, can be easily identified and treated, whereas
neumonia and worsening renal function (occurring in
lmost one-quarter of patients) were primarily comorbid
arkers of poorer prognosis.
Quality and content of the patient-provider interaction
as been critically evaluated in several studies this year.
atient recall of adherence advice at the time of hospital
ischarge from a HF admission was still dismal (97). Also,
atients with advanced HF may have a wide range of prefer-
nces when it comes to choosing between quality or quantity of
ife, and there may be a discrepancy between prognostic
xpectations of patients and their providers (98,99).
A very provocative report (100) on the cause of death in
atients with a diagnosis of HF from the Olmsted County
atabase highlights the core issue facing clinical investiga-
ors in HF. A heavy reliance on all-cause mortality as the
ost definitive end point has been called into question, as
areful evaluation of noncardiac causes of death ranged from
6% in those with systolic HF to almost one-half (49%) in
iastolic HF. Clearly, any therapeutic intervention that acts
n specific pathways to mediate cardiovascular benefits will
ikely be effective in a subset of individuals. We should, to
ome extent, be wary of all-cause mortality as an end point,
articularly in older patients with HFpEF, many of whom
an die from noncardiac causes.
onclusions
he reliance on mega-trials to formulate clinical evidence
or the treatment of HF over the past decades is beginning
o wane. Clearly, the role of genetic, biochemical, and
chocardiographic profiling is increasingly important. The
utcome measures themselves have been challenged. We
hould embrace these challenges as opportunities rather
han frustrations and should always remind ourselves that
he road to beta-blocker as HF therapy took more than 2
ecades and many detours to reach broad adoption. We
ust continue to learn to better interpret our existing data
nd to explore how to predict responsiveness to therapies
sing emerging molecular and genetic techniques.
Rapid technological advances have broadened HF care
nto a highly skilled expertise that requires specialist train-
ng, and this year we witnessed updates of cardiology
raining requirements for HF and cardiac transplantation
101), as well as an ongoing move toward specialist accred-
tation by the American Board of Internal Medicine. This is
learly an exciting new era, one that legitimizes training in
he complex field of HF. It is hoped that this era will inspire
generation of new ideas and more innovations.
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